09.02.2019 · Earlier, Blueprint had announced an expansion of the trial, wherein the recruitment target for patients previously treated with imatinib and at least one additional tyrosine kinase inhibitor (TKI) was increased from 50 to 100 patients, and a new cohort was added, to investigate avapritinib in second-line GIST.
07.12.2021 · FDA approves avapritinib for advanced systemic mastocytosis. On June 16, 2021, the Food and Drug Administration approved avapritinib (Ayvakit™, Blueprint Medicines Corp.) for adult patients with ...
• Avapritinib is an investigational agent discovered and currently in development by Blueprint Medicines Corporation (Blueprint Medicines) • Data are preliminary and based on a cutoff date of October 15, 2018 • Dr. Michael Heinrich is an investigator for Blueprint Medicines’ ongoing
On June 16, 2021, the Food and Drug Administration approved avapritinib (Ayvakit™, Blueprint Medicines Corp.) for adult patients with advanced systemic ...
AYVAKIT (avapritinib) is a prescription medication used to treat adult patients ... resident and you agree to receive information about Blueprint Medicines, ...
• Avapritinib investigators and research coordinators • Colleagues at Blueprint Medicines Corporation • Medical writing support and editorial support were provided by Deborah Cantu, PhD, and Travis Taylor, BA, both of Paragon, UK, supported by …
09.01.2020 · Avapritinib is not approved for the treatment of any other indication in the U.S. or any other jurisdiction by the FDA or any other health authority. Blueprint Medicines is pursuing a broad clinical development program for avapritinib across multiple lines of GIST treatment, as well as for advanced, smoldering and indolent systemic mastocytosis ...
The FDA granted approval of Ayvakit to Blueprint Medicines Corporation. Avapritinib was approved based on the results from the Phase I NAVIGATOR clinical ...
Blueprint Medicines is developing avapritinib as a potential treatment for a broad population of patients with SM globally, including advanced and non-advanced SM. View approved uses of avapritinib. View clinical trials of avapritinib. Presentations and publications. Avapritinib in GIST.